Pancreatic Cancer Research

ResearcherUniversity of HelsinkiActive in the last 2 years

Akseli Hemminki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7103-8530; OpenAlex author ID A5062078543. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
8
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 3

  1. Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models. Last author DOI 10.1007/s00262-025-04072-6↗
  2. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. Co-author DOI 10.1172/jci.insight.99573↗
  3. Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer. Last author DOI 10.1002/ijc.26370↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Santeri Artturi Pakola · 1 shared paper, 2025 · strength 0.20
  2. Hanna E. Seppänen · 1 shared paper, 2025 · strength 0.20
  3. Pauli Antero Puolakkainen · 1 shared paper, 2025 · strength 0.20
  4. Keisuke Watanabe · 1 shared paper, 2018 · strength 0.07
  5. John Scholler · 1 shared paper, 2018 · strength 0.07
  6. Carl H. June · 1 shared paper, 2018 · strength 0.07
  7. Tuula A. Kiviluoto · 1 shared paper, 2012 · strength 0.03
  8. Lotta Kangasniemi · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.